Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial
Journal
The American journal of gastroenterology
Journal Volume
118
Journal Issue
7
Pages
1184
Date Issued
2023-07-01
Author(s)
Hsu, Ping-I
Chen, Kuan-Yang
Tai, Wei-Chen
Tsay, Feng-Woei
Liu, Yu-Hwa
Chen, Chien-Lin
Lee, Chia-Long
Yeh, Hong-Zen
Kuo, Chao-Hung
Chuah, Seng-Kee
Lee, Hsi-Chang
Shie, Chang-Bih
Shiu, Sz-Iuan
Kao, John Y
Yamaoka, Yoshio
Graham, David Y
Wu, Deng-Chyang
Abstract
The study aimed to compare the efficacies and safety of 14-day hybrid therapy, 14-day high-dose dual therapy, and 10-day bismuth quadruple therapy in the first-line treatment of Helicobacter pylori infections.
Subjects
antibiotic resistance | bismuth quadruple therapy | CYP2C19 | Helicobacter pylori | high-dose dual therapy | hybrid therapy
SDGs
Type
journal article